Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regenerx Biopharmaceuticals, which focuses on the discovery and development of molecules to promote tissue and organ repair, has completed enrollment of its first of four ongoing Phase II clinical trials.
Subscribe to our email newsletter
The trial is a double-blind, placebo-controlled, dose-escalating clinical study evaluating the safety and efficacy of the company’s topical drug candidate, RGN-137, in 72 patients with pressure ulcers who are being treated for up to 84 days or less if fully healed.
RGN-137 is a formulation of thymosin beta 4 specifically for topical delivery to dermal wounds. Approximately 22 wound care centers and hospitals in the US have participated in the study. The company expects to report results in the fourth quarter of 2008.
David Crockford, vice president of clinical and regulatory affairs at RegeneRx, said: “Currently there are no pharmacological agents approved for improving the healing of pressure ulcers and we look forward to reporting the results once they are available.”